Green Square Capital buys $4,532,811 stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Green Square Capital scooped up 459 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 26, 2016. The investment management firm now holds a total of 69,843 shares of AbbVie Inc which is valued at $4,532,811.AbbVie Inc makes up approximately 1.10% of Green Square Capital’s portfolio.

Other Hedge Funds, Including , Hl Financial Services boosted its stake in ABBV in the latest quarter, The investment management firm added 22,108 additional shares and now holds a total of 420,788 shares of AbbVie Inc which is valued at $27,309,141. AbbVie Inc makes up approx 0.63% of Hl Financial Services’s portfolio.Yhb Investment Advisors reduced its stake in ABBV by selling 478 shares or 1.09% in the most recent quarter. The Hedge Fund company now holds 43,425 shares of ABBV which is valued at $2,770,949. AbbVie Inc makes up approx 0.59% of Yhb Investment Advisors’s portfolio.Lynch Associatesin boosted its stake in ABBV in the latest quarter, The investment management firm added 2,585 additional shares and now holds a total of 62,455 shares of AbbVie Inc which is valued at $3,985,254. AbbVie Inc makes up approx 1.74% of Lynch Associatesin’s portfolio.Willingdon Wealth Management boosted its stake in ABBV in the latest quarter, The investment management firm added 2,096 additional shares and now holds a total of 39,839 shares of AbbVie Inc which is valued at $2,542,127. AbbVie Inc makes up approx 1.26% of Willingdon Wealth Management’s portfolio.Private Vista boosted its stake in ABBV in the latest quarter, The investment management firm added 111 additional shares and now holds a total of 4,313 shares of AbbVie Inc which is valued at $273,487. AbbVie Inc makes up approx 0.09% of Private Vista’s portfolio.

AbbVie Inc opened for trading at $65.27 and hit $66.4 on the upside on Friday, eventually ending the session at $66.23, with a gain of 2.33% or 1.51 points. The heightened volatility saw the trading volume jump to 1,05,25,016 shares. Company has a market cap of $107,118 M.

On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *